We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
With support from the founders of Bulldog Skincare, Zoopla and Love Film, VITL's aim is to improve the nation's health by offering vitamin packs that are fully personalised to the customer. VITL uses artificial intelligence to decipher which nutrients a person needs to ensure a healthy lifestyle. Effectively cutting out the cost of a private nutritionist.

Pitch Rated

44%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £908,950
Rabble is a gamified and licensed fitness program that transforms exercise into fun, team-based games. It was first formed by a former international athlete and then financed by investors from the LA Fitness & Liverpool football club. Rabble has quickly risen to 100 authorized sites strengthening many healthy communities over the UK. It is a differentiated concept which is named as Global Fitness Trend (WGSN). It has a proven and scalable model where the market leaders earn revenue of more than $100m. Further, it has developed 100+ instructors across the UK in less than one year. Rabble aims at helping and changing more lives with the finance that it raises. It is planning to grow to more than 300 Rabble sites in the coming year.
days to go: Expired investment: £274,530
HealthBox Software is a technology company building products for the post-COVID healthcare landscape. Its first product, ClearPass, was met with success. The tool asks an employee a series of screening questions related to COVID-19, including evidence of fever, fatigue, and dry cough, etc. ClearPass has over 400,000 end-users including companies like Johnson Controls, Remy Cointreau and the San Diego School District. HealthBox aims to be a significant contender in the global digital health market that is expected to be worth $600 billion by 2026. The company is on the verge of launching another innovative product, MyHealthBox. It is a consumer-facing digital health app that will allow users to store their medical records, easily accessible 24/7. HealthBox asserts that the app will have an array of features, including AI health assessment services, dietary advice and data-powered lifestyle guidance. The company will use 47% of the investment towards technology and development costs, and 53% towards sales and marketing.

Pitch Rated

79%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £144,265
Gendius' has created intellin, an application through which people can track diabetes and make a good decision to reduce the risk of diabetes. It is on a mission to make sure that every person with diabetes knows their risk of complications and how to control them. The company has been launched across the EU with over 3,500 downloads in the EU and UK. In 2018, the company won £25K Momentum award to complete UX/UI research and, it has passed ISO27001. Recently, it has been invited to HIMSSHealth2.0 conference for the application's live demo.
days to go: Expired investment: £518,630
By combining fitness with fashion, art and design, BLOK has become a major competitor of boutique class-based gyms within London. BLOK has appeared on Britain's Next Top Model, as well as working with global stars including Anthony Joshua and Jordan Dunn.

Pitch Rated

60%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £891,790
Clinical Net is a health-tech firm focused on revolutionizing access to innovative clinical trials. Their AI platform swiftly connects patients with suitable trials, addressing the challenge of low participation rates and delays that hinder pharmaceutical research. With over 69,000 trials globally, their solution aims to streamline the cumbersome and time-consuming process of trial matching, making it more efficient and accessible within 5 minutes. This innovative approach targets the $3.73 billion patient recruitment market while ensuring individuals have easier access to groundbreaking treatments.
days to go: Expired investment: £136,827
niix is a fitness app plugging the gap in the market for women approaching 40. Since its launch in 2018, the company has created a 4+ star rated app with more than 1800 paid subscriptions across 25 countries including the US, Canada, and Australia. It also has an online following of tens of thousands. The global fitness app market is growing fast set to be worth $2 billion by 2023 with a focus on weight loss and body aesthetics for millennial markets. niix sees a huge opportunity in this space to support women who have simply outgrown an approach that want the perfect body and be fit lifelong. With the investment, the company will scale up proven marketing channels to grow community and subscriber bases, making niix the no.1 digital fitness brand for women approaching 40+.

Pitch Rated

72%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £153,441
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph